A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY -ALS (CY 4031)

Clinical Trial Grant

Duke Scholars

Principal Investigator Richard Stanley Bedlack Neurology, Neuromuscular Disease

Administered By

Neurology

Awarded By

Cytokinetics, Inc.

Start Date

December 1, 2016

End Date

April 13, 2018

Administered By

Neurology

Awarded By

Cytokinetics, Inc.

Start Date

December 1, 2016

End Date

April 13, 2018